The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

Table 1 Baseline characteristics and disease activity of patients included in analysis

Data are mean (SD) unless otherwise stated
ACPA anti-citrullinated peptide antibody; ACR20/50 20/50% improvement according to the criteria of the American College of Rheumatology; BMI body mass index; CV coefficient of variation (statistical measure of dispersion of data relative to the mean since these biomarker data follow a lognormal distribution; thus, the standard deviation does not adequately capture the nature of the dispersion of the data; C1M metalloproteinase-derived fragments of type I, of type II (C2M), type III (C3M), and type IV (C4M) collagen; CRP C-reactive protein; CTX-I C-terminal telopeptide of type I collagen; DAS28 Disease Activity Score 28 joints; ESR erythrocyte sedimentation rate; HAQ-DI Health Assessment Questionnaire-Disability Index; mTSS modified Total Sharp Score; RF rheumatoid factor; SD standard deviation
^aTime from RA diagnosis
^bMean for ACPA, RF, and biomarkers was calculated as the geometric mean

ISSN: 1478-6362